OBJECTIVES: The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in. METHODS: Eligible participants received OL GLM in period 1. In period 2, participants who achieved inactive disease were randomized 1:1:1 to receive double-blind (DB) treatment with monthly placebo (PBO, treatment withdrawal) or continued GLM treatment given monthly (GLM QMT) or every 2 months (GLM Q2MT). Participants who did not have a disease flare continued DB treatment for ∼12 months. Participants with a disease flare discontinued DB treatment and resumed monthly OL GLM. Primary endpoint compared the proportion of participants without a disease flare in the continued GLM treatment groups (QMT or Q2MT) vs PBO in a multiplicity-controlled, step-down fashion. Safety follow-up continued for ∼3 months after last treatment. RESULTS: A total of 188 patients, out of the 323 enrolled, were eligible for participation in period 2. Both GLM QMT and GLM Q2MT were superior to treatment withdrawal (PBO) in preventing disease flare (P < 0.001), with a treatment-difference vs PBO of 50.4% and 34.4% for the GLM QMT and GLM Q2MT groups, respectively. The time-to-first flare was significantly longer (log-rank P < 0.0001) with GLM treatment compared with PBO. Of 53 participants (in Q2MT or PBO) who had a confirmed disease flare, 51 (96.2%) attained a clinical response within 3 months of restarting OL GLM. Adverse events were consistent with the known GLM safety profile. CONCLUSION: Among participants with active nr-axSpA who attained inactive disease after 10 months of GLM treatment, continued GLM treatment is well tolerated and provides superior protection against disease flares compared with GLM withdrawal. (EudraCT: 2015-004020-65, registered on 30 March 2022; NCT: 03253796, registered on 18 August 2017.).

CCR Czech a s Pardubice Czech Republic

Merck and Co Inc Rahway NJ USA

MSD Zurich Switzerland

Reumatika Centrum Reumatologii Warsaw Poland

Vladimirsky Moscow Regional Scientific Institution Moscow Russia

See more in PubMed

Sieper J, Poddubnyy D.. Axial spondyloarthritis. Lancet 2017;390:73–84. PubMed

Ward MM, Deodhar A, Gensler LS. et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2019;71:1599–613. PubMed PMC

Ramiro S, Nikiphorou E, Sepriano A. et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2022;82:19–34. PubMed

Robinson PC, van der Linden S, Khan MA, Taylor WJ.. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol 2021;17:109–18. PubMed

van der Heijde D, Ramiro S, Landewé R. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91. PubMed

Sieper J, van der Heijde D, Dougados M. et al. A randomized, double‐blind, placebo‐controlled, sixteen‐week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2015;67:2702–12. PubMed PMC

van der Heijde D, Dougados M, Maksymowych WP. et al. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. Rheumatology (Oxford) 2022;61:617–27. PubMed

Smolen JS, Braun J, Dougados M. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16. PubMed PMC

Kiltz U, Baraliakos X, Braun J, van der Heijde D.. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design? Clin Exp Rheumatol 2013;31(Suppl 78):S47–50. PubMed

Song I-H, Haibel H, Poddubnyy D, Braun J, Sieper J.. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013;31(Suppl 78):S37–42. PubMed

Landewé R, Sieper J, Mease P. et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 2018;392:134–44. PubMed

Landewé RBM, van der Heijde D, Dougados M. et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis 2020;79:920–8. PubMed PMC

Lawson DO, Eraso M, Mbuagbaw L. et al. Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2021;73:861–72. PubMed

Leu JH, Adedokun OJ, Gargano C. et al. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford) 2019;58:441–6. PubMed

Adedokun OJ, Gunn GR, Leu JH. et al. Immunogenicity of golimumab and its clinical relevance in patients with ulcerative colitis. Inflamm Bowel Dis 2019;25:1532–40. PubMed

Ruperto N, Brunner HI, Pacheco-Tena C. et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2021;60:4495–507. PubMed PMC

Plasencia C, Pascual-Salcedo D, Nuno L. et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955–60. PubMed

Bartelds GM, Wijbrandts CA, Nurmohamed MT. et al. Clinical response to adalimumab: relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921–6. PubMed PMC